These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15641121)

  • 1. Managing the risks of therapeutic products: proceedings of a workshop.
    Kramer JM
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):619-28. PubMed ID: 15641121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk assessment of drugs, biologics and therapeutic devices: present and future issues.
    Centers for Education and Research on Therapeutics Risk Assessment Workshop
    Pharmacoepidemiol Drug Saf; 2003 Dec; 12(8):653-62. PubMed ID: 14762981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.
    Flynn MA; McNeil DA; Maloff B; Mutasingwa D; Wu M; Ford C; Tough SC
    Obes Rev; 2006 Feb; 7 Suppl 1():7-66. PubMed ID: 16371076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of scientific evidence of risks and benefits in determining risk management policies for medications.
    Andrews E; Dombeck M
    Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):599-608. PubMed ID: 15362082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics.
    Califf RM;
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):5-16. PubMed ID: 16506270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Social policy and drug safety.
    Tilson HH
    Clin Geriatr Med; 1986 Feb; 2(1):165-80. PubMed ID: 3513933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
    Wright C; Schnoll S; Bernstein D
    Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exception from informed consent: viewpoint of institutional review boards--balancing risks to subjects, community consultation, and future directions.
    Ernst AA; Fish S
    Acad Emerg Med; 2005 Nov; 12(11):1050-5. PubMed ID: 16264073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. State of the science on implant dentistry: a workshop developed using an evidence-based approach.
    Iacono VJ; Cochran DL
    Int J Oral Maxillofac Implants; 2007; 22 Suppl():7-10. PubMed ID: 18437788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Criteria supporting the study of drugs in the newborn.
    Ward RM; Benitz WE; Benjamin DK; Blackmon L; Giacoia GP; Hudak M; Lasky T; Rodriguez W; Selen A
    Clin Ther; 2006 Sep; 28(9):1385-98. PubMed ID: 17062311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naturally occurring asbestos: a recurring public policy challenge.
    Lee RJ; Strohmeier BR; Bunker KL; Van Orden DR
    J Hazard Mater; 2008 May; 153(1-2):1-21. PubMed ID: 18180100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The International Liaison Committee on Resuscitation (ILCOR) consensus on science with treatment recommendations for pediatric and neonatal patients: pediatric basic and advanced life support.
    International Liaison Committee on Resuscitation
    Pediatrics; 2006 May; 117(5):e955-77. PubMed ID: 16618790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S; Roberts R
    J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and control of food safety risks: the role of governments, food producers, marketers, and academia.
    Lupien JR
    Asia Pac J Clin Nutr; 2007; 16 Suppl 1():74-9. PubMed ID: 17392080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring opportunities for collaboration between the corporate sector and the dental education community.
    Alexander D; Clarkson J; Buchanan R; Chadwick G; Chesters R; Drisko CL; Douglass CW; Farrell L; Fletcher K; Makoni F; Monaco M; Nordquist B; Park NI; Riggs S; Schou L; Smales FC; Stamm JW; Toh CG; Volpe T; Ward P; Warren P
    Eur J Dent Educ; 2008 Feb; 12 Suppl 1():64-73. PubMed ID: 18289269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.